Considerations for treatment duration in responders to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Marron, Thomas U, Ryan, Aideen E, Reddy, Sangeetha M, Kaczanowska, Sabina, Younis, Rania H, Thakkar, Dipti, Zhang, Jiajia, Bartkowiak, Todd, Howard, Rachel, Anderson, Kristin G, Olson, Daniel, Naqash, Abdul Rafeh, Patel, Ravi B, Sachdev, Esha, Rodriguez-Ruiz, Maria E, Sheffer, Michal, Church, Sarah, Fuhrman, Christopher, Overacre-Delgoffe, Abigail, Nguyen, Rosa, Florou, Vaia, Thaxton, Jessica E, Aggen, David H, Guerriero, Jennifer L
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929825/
https://ncbi.nlm.nih.gov/pubmed/33653801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001901
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados